Innogen Pharmaceuticals Enters Into Licensing Agreement with Arcera Life Sciences for Efsubaglutide Alfa, Accelerating International Expansion
The agreement gives Arcera rights to pursue approvals and commercialization of Efsubaglutide Alfa in selected markets, with payments worth more than $1 billion.
6 Articles
6 Articles
HK-listed Guangzhou Innogen signs over $1 billion licensing deal for diabetes drug - Regional Media News
Nov 19 (Reuters) - Hong Kong-listed Guangzhou Innogen Pharmaceutical said on Thursday it signed a licence agreement worth more than $1 billion with Arcera Life Sciences to commercialise its GLP-1 receptor agonist drugs used to treat patients with type 2 diabetes. The deal will allow [...]
Innogen Pharmaceuticals Enters into Licensing Agreement with Arcera Life Sciences for Efsubaglutide Alfa, Accelerating International Expansion
Under the agreement, Arcera will obtain exclusive rights to Efsubaglutide Alfa in selected countries in Africa, Latin America, the Middle East and Eastern Europe, while Innogen retains the relevant rights in the rest of the world.Under the agreement, Innogen will…
Arcera Life Sciences and Innogen Pharmaceuticals Sign Exclusive Licensing Agreement to Expand Access to Cardiometabolic Care Across International Markets
Abu Dhabi, UAE / Hong Kong, China, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Arcera Life Sciences (“Arcera”), an international life sciences company headquartered in Abu Dhabi, UAE, and Innogen Pharmaceuticals (“Innogen”) (HKEX: 2591), a Shanghai-based biopharmaceutical company focused on metabolic…
Coverage Details
Bias Distribution
- 40% of the sources lean Left, 40% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium








